


## PHARMACEUTICAL 2018



## Merck & Co. Inc. Rank 28 of 349







## PHARMACEUTICAL 2018



## Merck & Co. Inc. Rank 28 of 349



The relative strengths and weaknesses of Merck & Co. Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Merck & Co. Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 342% points. The greatest weakness of Merck & Co. Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 68% points.

The company's Economic Capital Ratio, given in the ranking table, is 163%, being 440% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	24,766,000
Cost of Goods Sold	0
Intangible Assets	32,467,000
Liabilities, Current	18,614,000
Liabilities, Non-Current	0
Other Assets	18,200,000
Other Compr. Net Income	292,000
Other Expenses	17,666,000
Other Liabilities	0
Other Net Income	0
Property and Equipment	12,439,000
Research and Development	10,208,000
Revenues	40,122,000
Selling, General and Administrative Expense	9,830,000

Output Variable	Value in 1000 USD
Assets	87,872,000
Liabilities	18,614,000
Expenses	37,704,000
Stockholders Equity	69,258,000
Net Income	2,418,000
Comprehensive Net Income	2,564,000
Economic Capital Ratio	163%